Table 2.
Identified differential metabolites between the antenatal depression and non-antenatal depression groups
| Metabolites | AD vs NAD | |||||
|---|---|---|---|---|---|---|
| ESI+/− | FC | FDR | VIP | P-value | Bonferroni corrected | |
| SM (d18:1/16:0) | + | 1.88 | < 0.001 | 5.07 | < 0.001 | < 0.001 |
| SM (d16:1/18:0) | + | 2.27 | < 0.001 | 5.42 | < 0.001 | < 0.001 |
| 9Z-Heptatriacontene | + | 2.03 | < 0.001 | 8.09 | < 0.001 | < 0.001 |
| PC (16:0/0:0) | – | 2.00 | < 0.001 | 2.20 | < 0.001 | < 0.001 |
| EB 1213 | + | 3.30 | < 0.001 | 3.83 | < 0.001 | < 0.001 |
| 3alpha-Hydroxy-7-oxo-5alpha-cholan-24-oic Acid | + | 2.55 | 0.001 | 3.72 | 0.001 | 0.035 |
| PC (22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0) | + | 2.65 | 0.001 | 1.38 | 0.002 | 0.07 |
| cholesterol sulfate | – | 2.49 | 0.001 | 1.46 | 0.003 | 0.105 |
| PC (18:2(2E,4E)/0:0) | + | 2.70 | 0.001 | 1.12 | 0.003 | 0.105 |
| LMST03020057 | + | 2.48 | 0.001 | 3.84 | 0.004 | 0.14 |
| PC(16:0/0:0) | – | 2.07 | 0.001 | 1.57 | 0.004 | 0.14 |
| PC(0:0/18:0) | – | 2.03 | 0.027 | 1.58 | 0.004 | 0.14 |
| Hexan-1-ol | + | 3.61 | 0.001 | 2.83 | 0.006 | 0.21 |
| PE(13:0/22:1(11Z)) | + | 2.34 | 0.001 | 1.16 | 0.006 | 0.21 |
| LysoPE (0:0/18:2(9Z,12Z)) | + | 2.29 | 0.001 | 1.01 | 0.006 | 0.21 |
| 1,25-Dihydroxy-23-oxo-vitamin D3 | + | 2.04 | 0.001 | 1.72 | 0.007 | 0.245 |
| SM(d16:1/16:0) | – | 2.36 | 0.001 | 1.35 | 0.007 | 0.245 |
| Undecylic acid | + | 2.44 | 0.001 | 0.97 | 0.008 | 0.28 |
| SM(d18:1/15:0) | + | 2.18 | 0.001 | 1.55 | 0.009 | 0.315 |
| 5-amino-pentanoic acid | + | 2.01 | 0.001 | 1.03 | 0.009 | 0.315 |
| Sorbitan stearate | + | 4.45 | 0.001 | 1.46 | 0.009 | 0.315 |
| SM(d16:1/20:1) | – | 2.06 | 0.001 | 1.20 | 0.009 | 0.315 |
| PC(18:1(9Z)/0:0) | + | 2.29 | 0.001 | 3.48 | 0.010 | 0.35 |
| LysoPC (20:3(5Z,8Z,11Z)) | + | 2.25 | 0.001 | 1.56 | 0.010 | 0.35 |
| PE(8:0/8:0) | + | 3.16 | 0.001 | 1.83 | 0.010 | 0.35 |
| Etretinate | – | 3.34 | 0.001 | 1.21 | 0.011 | 0.315 |
| 13-amino-tridecanoic acid | + | 3.08 | 0.001 | 3.78 | 0.011 | 0.315 |
| 6-deoxyerythronolide B | + | 4.77 | 0.001 | 2.60 | 0.013 | 0.455 |
| PE(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | 2.07 | 0.002 | 1.72 | 0.015 | 0.525 |
| (7Z,10Z)-hexadecadienoylcarnitine | + | 3.64 | 0.002 | 1.53 | 0.016 | 0.56 |
| 12-amino-dodecanoic acid | + | 2.47 | 0.002 | 3.66 | 0.017 | 0.595 |
| 5-((5Z,8Z,11Z,14Z)-heptadeca-5,8,11,14-tetraen-1-yl)resorcinol | – | 4.58 | 0.002 | 1.33 | 0.017 | 0.595 |
| MG(0:0/18:1(9Z)/0:0) | + | 2.13 | 0.002 | 7.62 | 0.027 | 0.945 |
| 1-Heptene | + | 0.47 | 0.003 | 3.77 | 0.034 | 1.19 |
| 8-methoxy-13-hydroxy-9,11-octadecadienoic acid | + | 2.03 | 0.003 | 1.47 | 0.034 | 1.19 |
AD antenatal depression, NAD non-antenatal depression, ESI electrospray ionization, FC fold change, FDR false discovery rate, VIP variable importance in the projection